PORTLAND, Ore., January 10, 2019 (Newswire.com) – Nobilis Therapeutics, a biopharmaceutical company focused on the advancement of innovative Central Nervous System therapies based upon the use of noble gas mixtures, today announced that it has entered into a collaboration with The Linde Group to support its ongoing clinical research program to study a drug / device combination for treatment of patients with Post-Traumatic Stress Disorder (PTSD).
Under this agreement, Nobilis Therapeutics and Linde will work together to develop options around the potential for future supply, manufacturing and commercialization opportunities for the product in the US, Europe, Latin America and Asia Pacific markets. The two companies will establish a joint steering committee to collaborate regarding the ongoing research and development plans. Terms of the deal are not disclosed.
“Our preclinical and early efficacy studies in PTSD, Panic Disorder, Autism Spectrum Disorder suggest the general potential for such drug/device combination to be a promising therapeutic option for the treatment of patients with Post-Traumatic Stress Disorder and potentially other psychiatric and neurodegenerative conditions” said Dr. Vlad Bogin, Founder and CEO of Nobilis Therapeutics.
Urmi Prasad Richardson, Global Head of Healthcare in Linde’s Centre of Excellence, added, “We are very pleased to partner with Nobilis Therapeutics to advance the research for treatment of patients with Post Traumatic Stress Disorder”.
Nobilis’s research for the treatment of patients with Post-Traumatic Stress Disorder focuses on a proprietary inhalation-based treatment using portable device administration of a xenon gas mixture.
About Nobilis Therapeutics
Nobilis Therapeutics is a biotechnology company that is focused on development and commercialization of proprietary inhalation-based treatments using controlled device administration of inert gases. The Company has filed multiple patents on the use of inert gases for treatment of a variety of psychiatric and neurodegenerative diseases and leverages the experience of its international team that has studied this technology in the treatment of over 2000 patients for conditions ranging from panic attacks to substance abuse. The Company has filed an IND to initiate a phase IIb/III clinical trial to evaluate the efficacy of NBTX-001, its lead compound, for the treatment of patients with PTSD.
For more information please visit Nobilis Therapeutics online at www.nobilistx.com
About Linde Healthcare
Linde Healthcare is a global leader specializing along an integrated respiratory care path. It combines pharmaceutical gases, medical devices, services and clinical care into solutions with the patient in mind. Its products and services make a difference in the lives of its patients and to its healthcare partners in the care continuum from hospital to home. A global business unit of The Linde Group, it is present in over 60 countries and generated revenues of EUR 3.361bn in 2017.
For more information, visit Linde Healthcare online at www.linde-healthcare.com
About The Linde Group
In the 2017 financial year, The Linde Group generated revenue of EUR 17.113 bn, making it one of the leading gases and engineering companies in the world, with approximately 58,000 employees working in more than 100 countries worldwide. The strategy of The Linde Group is geared towards long-term profitable growth and focuses on the expansion of its international business, with forward-looking products and services. Linde acts responsibly towards its shareholders, business partners, employees, society and the environment in every one of its business areas, regions and locations across the globe. The company is committed to technologies and products that unite the goals of customer value and sustainable development.
For more information, see The Linde Group online at www.linde.com
Global Healthcare Portfolio Coordinator
Tel: (971) 229-1679